UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
A new generation of Alzheimer’s treatments — groundbreaking, disease-modifying monoclonal antibody drugs — is on the rise, and two so far have hit the…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…
As I prepared to board the plane to Amsterdam for the Alzheimer’s Association International Conference, an email from the news site Axios caught my…
In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
Gordon Van Slyke’s mother and sister both passed away of early onset Alzheimer’s when they were in their early 60s. When he decided to…
UPDATE: 3 March 2024, 8:16 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
Lecanemab, Eisai and Biogen’s experimental anti-amyloid Alzheimer’s drug, which recently wrapped its Phase 3 clinical trials, continues to make the news. Some of these…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…
Update 27 January, 2023: In January 2023, lecanemab was granted accelerated approval by the FDA and made available to patients under the brand name…
According to an Eisai press release, the U.S. Food and Drug Administration has now granted priority review to a new anti-amyloid drug by Biogen…
The biotechnology company Eisai Co., Ltd. announced a rolling submission for accelerated approval from the Food and Drug Administration for their anti-amyloid Alzheimer’s treatment,…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…